TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03623815

Intervention type: OTHER
Group type: OTHER
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered.

Intervention type: OTHER
Group type: OTHER
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered.
Study: NCT03578861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia related mobility and counseling
Description: The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments.
Study: NCT03809143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
Study: NCT02582502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: The only intervention given will be 100% oxygen under hyperbaric pressure.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric Oxygen
Description: The only intervention given will be 100% oxygen under hyperbaric pressure.
Study: NCT02885012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
Study: NCT02206048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: 0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy (HRME) Imaging
Description: in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
Study: NCT04412408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)
Study: NCT00075010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 15 mg/m\^2 by vein over 1 hour times 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 20 mg/kg given orally daily for 10 days
Study: NCT04943315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia
Description: posterior crowns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic
Description: posterior crowns
Study: NCT00595530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation.
Study: NCT01565512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
Study: NCT01260636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: 0.1 mmol/kg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate Dimeglumine
Description: Double dose of 0.2 mmol/kg
Study: NCT02495298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Fascial Manipulation
Description: After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
Study: NCT01235351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily, 150 mg daily
Study: NCT03600545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness App
Description: Brain exercises using an iPAD
Study: NCT02079220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A
Description: * Capecitabine~* Oxaliplatin~* Ziv-aflibercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B
Description: Capecitabine Oxaliplatin Ziv-aflibercept
Study: NCT03394326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-based obesity prevention lifestyle intervention
Description: A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
Study: NCT02951728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03394326

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: family-based obesity prevention lifestyle intervention
Description: A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
Study: NCT01340885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strattera
Description: 10-30 mg b.i.d. for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon
Description: 1.5-4.5 mg b.i.d. for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-6 pills for 6 weeks
Study: NCT04256798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: 0.2% Chlorhexidine digluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: 0.2% Chlorhexidine digluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen 80-100%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen 80-100%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen 21-30 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen 21-30 %
Study: NCT02505997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
Study: NCT03748797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training under supervision
Description: Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
Study: NCT00940225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04388618

Intervention type: OTHER
Intervention: NHANES smell and taste tests
Description: participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected

Intervention type: OTHER
Intervention: NHANES smell and taste tests
Description: participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
Study: NCT04249583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: neuromodulator to be injected in the GL region

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be injected in the GL area
Study: NCT01004627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial and venous duplex ultrasound examination
Description: Ultrasound mapping of all blood vessels in the upper limb of interest
Study: NCT03636932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Circulating tissue factor assay

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: Circulating tissue factor assay

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: The test of pro-coagulant activity of the tissue factor

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: The test of pro-coagulant activity of the tissue factor
Study: NCT02835924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study: NCT01661296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RFH therapy
Description: RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate
Description: Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
Study: NCT04070274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different types of surgery platforms
Description: 58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different types of surgery platforms
Description: 58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
Study: NCT01504035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthostat-L
Description: Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthostat
Description: Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
Study: NCT05604118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1 week of aspirin supplementation prior to sampling
Study: NCT02824874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg
Description: Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg
Description: Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg + Januvia Tab. 100mg
Description: Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg + Januvia Tab. 100mg
Description: Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
Study: NCT00806390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metroprolol tartrate titrated up
Study: NCT01925300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concor 5mg 2T and Crestor 20 mg 1Tab
Study: NCT02242032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-321 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-321 Ophthalmic Solution placebo
Description: Placebo to match P-321 Ophthalmic Solution
Study: NCT02951728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT02689089

Intervention type: DRUG
Group type: OTHER
Intervention: 3HP
Description: An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
Study: NCT01023516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg oral tablets bd for 12 weeks
Study: NCT03972046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (MEK Inhibitor)
Description: Trametinib (MEK Inhibitor) 2 mg by mouth once a day
Study: NCT01023516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x matched placebo to oral tablet bd for 12 weeks
Study: NCT02023541

Intervention type: RADIATION
Group type: OTHER
Intervention: Proton beam therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Proton beam therapy
Study: NCT03529175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane (nab-paclitaxel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane (nab-paclitaxel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT01282892

Intervention type: PROCEDURE
Intervention: excess of visceral fat
Description: excess of visceral fat

Intervention type: PROCEDURE
Intervention: patients with NAFLD
Description: patients with NAFLD
Study: NCT03647397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photo Electrochemical Oxidation (PECO) for Air Purification
Description: PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
Study: NCT02950532

Intervention type: OTHER
Intervention: Retrospective radiological evaluation
Description: Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
Study: NCT02980601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integra plus STSG
Description: A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
Study: NCT01822249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03746938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VB-C01
Description: Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
Study: NCT01917591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsies treated with MariGen Wound ECM dressing
Description: Weekly dressing changes and review of wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch biopsies treated with Oasis ECM dressing
Description: Weekly dressing changes and wound review
Study: NCT03814460

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Tone, Pain and Thickness
Description: Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Tone, Pain and Thickness
Description: Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Tone, Pain and Thickness
Description: Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
Study: NCT00269620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/etonogestrel vaginal ring
Description: vaginal ring for cyclic use (3 weeks in, 1 week out)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/norelgestromin transdermal contraceptive
Description: contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
Study: NCT02820480

Intervention type: DEVICE
Intervention: Rehab in a Crate System
Description: The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use.
Study: NCT03456414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise during hemodialysis
Description: Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
Study: NCT05233423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compressed cold therapy bandage
Description: Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
Study: NCT02980601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STSG
Description: 0.012mm STSG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STSG
Description: 0.012mm STSG
Study: NCT03475537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: the treatment of transcranial direct current stimulation
Study: NCT02747095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQon Spectral CT
Description: Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images